RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)

Recruiting

Phase 2

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)

Sponsor:

AbbVie

Code:

NCT04567550

Conditions

Diabetic Retinopathy (DR)

Center-Involved Diabetic Macular Edema (CI-DME)

Eligibility Criteria

Sex: All

Age: 25 - 70+

Healthy Volunteers: Not accepted

Interventions

ABBV-RGX-314 Dose 1

ABBV-RGX-314 Dose 2

ABBV-RGX-314 Dose 3

Topical Steroid

ABBV-RGX-314 Dose 4

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-09. This information was provided to ClinicalTrials.gov by AbbVie on 2025-03-19.